Literature DB >> 12182996

How fast is repopulation of tumor cells during the treatment gap?

Rafal Tarnawski1, Jack Fowler, Krzysztof Skladowski, Andrzej Swierniak, Rafal Suwiński, Boguslaw Maciejewski, Andrzej Wygoda.   

Abstract

PURPOSE/
OBJECTIVE: Our goal was to analyze the repopulation of surviving tumor cells during a treatment gap in radiotherapy for head-and-neck cancer. METHODS AND MATERIALS: Clinical material is based on the records of 1502 patients treated by radiotherapy alone in Maria Sklodowska-Curie Memorial Institute in Gliwice during the period between1980 and 1989. All patients had histologically confirmed squamous cell carcinoma of the larynx or pharynx. The mean gap duration was 9 days. Only 10% of patients were treated without gaps. The dose per fraction was in the range of 1.5 to 2.5 Gy. Patient data were fitted directly to the mixed linear-quadratic model using maximum-likelihood estimation. Tumor stage or tumor localization was introduced into the equation as a categorical variable. Tumor proliferation was estimated by dividing the treatment gaps into three groups: the first 2 weeks, second 2 weeks, and the period after 4 weeks of irradiation.
RESULTS: Tumor control probability was significantly correlated with radiation dose, tumor progression (according to TNM), overall treatment time, and gap duration. Laryngeal cancers had a better prognosis than cancers of the oro- and nasopharynx. Significant tumor repopulation was found after the first 2 weeks of radiotherapy. During the treatment gap, the proliferation rate was equal to 0.75 Gy/day. During the days with irradiation, repopulation was slower and equal to 0.2 Gy/day.
CONCLUSION: The repopulation of tumor cells is faster during a gap than during the normal days of irradiation. Accelerated repopulation probably starts soon after 2 weeks of irradiation.

Entities:  

Mesh:

Year:  2002        PMID: 12182996     DOI: 10.1016/s0360-3016(02)02936-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study.

Authors:  Amal Ahmed-Fouad Halim; Hanan Ahmed Wahba; Hend Ahmed El-Hadaad; Ahmed Abo-Elyazeed
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

2.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

3.  Computerized patient-reported symptom assessment in radiotherapy: a pilot randomized, controlled trial.

Authors:  Erik K Fromme; Emma B Holliday; Lillian M Nail; Karen S Lyons; Michelle R Hribar; Charles R Thomas
Journal:  Support Care Cancer       Date:  2015-10-16       Impact factor: 3.603

4.  Gender-related differences in repopulation and early tumor response to preoperative radiotherapy in rectal cancer patients.

Authors:  Anna Gasinska; Piotr Richter; Zbigniew Darasz; Joanna Niemiec; Krzysztof Bucki; Krzysztof Malecki; Andrzej Sokolowski
Journal:  J Gastrointest Surg       Date:  2011-06-25       Impact factor: 3.452

Review 5.  Management of interruptions in radiotherapy treatments: Adaptive implementation in high workload sites.

Authors:  Gustavo Pozo; Maria Angeles Pérez-Escutia; Ana Ruíz; Alejandro Ferrando; Ana Milanés; Eduardo Cabello; Raul Díaz; Alejandro Prado; Jose Fermin Pérez-Regadera
Journal:  Rep Pract Oncol Radiother       Date:  2019-02-26

6.  Inhibition of the Continuum of Radiation-Induced Normal Tissue Injury by a Redox-Active Mn Porphyrin.

Authors:  Samuel R Birer; Chen-Ting Lee; Kingshuk Roy Choudhury; Kenneth H Young; Ivan Spasojevic; Ines Batinic-Haberle; James D Crapo; Mark W Dewhirst; Kathleen A Ashcraft
Journal:  Radiat Res       Date:  2017-05-18       Impact factor: 2.841

7.  A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.

Authors:  Pol M Specenier; Joost Weyler; Carl Van Laer; Danielle Van den Weyngaert; Jan Van den Brande; Manon T Huizing; Sevilay Altintas; Jan B Vermorken
Journal:  BMC Cancer       Date:  2009-08-06       Impact factor: 4.430

Review 8.  Cellular responses to EGFR inhibitors and their relevance to cancer therapy.

Authors:  Pinaki R Dutta; Amit Maity
Journal:  Cancer Lett       Date:  2007-03-23       Impact factor: 8.679

9.  Compliance to radiation therapy of head and neck cancer patients and impact on treatment outcome.

Authors:  B C Ferreira; P Sá-Couto; M C Lopes; L Khouri
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

Review 10.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature.

Authors:  José A González Ferreira; Javier Jaén Olasolo; Ignacio Azinovic; Branislav Jeremic
Journal:  Rep Pract Oncol Radiother       Date:  2015-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.